Fairvalue-Calculator Fairvalue-Calculator
EN DE

Chengdu Kanghua Biological Products Co (300841) Fair Value & Analysis

Healthcare · CN · Market cap 6.0B CNY

Price¥48.16
Fair Value¥37.23
Upside-22.7%
Quality95/100
Evidence: High Range ¥27.92 – ¥46.54

Analysis

Chengdu Kanghua Biological Products Co (300841) currently trades at ¥48.16, while our model-based Fair Value estimate is ¥37.23 — implying the stock looks roughly 22.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Products Co., Ltd. was founded in 2004 and is based in Chengdu, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.